Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 8/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 0.36 |
| ▸ | POLG | P54098 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130892 | 0.80 | ALB (0.57) | ALBCACNA1FLMNAMAPTCACNA1D | |
| SCHEMBL540862 | 0.80 | ALB (0.57) | ALBCACNA1FLMNAMAPTCACNA1D | |
| SCHEMBL231959 | 0.72 | DNMT1 (0.64) | DNMT1LMNAPDE3ADNMT3BFPR2 | |
| SCHEMBL21277431 | 0.72 | ALB (0.41) | ALBDNMT1CACNA1FLMNAMAPT | |
| SCHEMBL25837386 | 0.72 | DNMT1 (0.64) | DNMT1LMNAPDE3ADNMT3BFPR2 | |
| SCHEMBL231960 | 0.72 | DNMT1 (0.64) | DNMT1LMNAPDE3ADNMT3BFPR2 | |
| SCHEMBL21277401 | 0.72 | ALB (0.41) | ALBDNMT1CACNA1FLMNAMAPT | |
| SCHEMBL22299584 | 0.72 | DNMT1 (0.64) | DNMT1LMNAPDE3ADNMT3BFPR2 | |
| SCHEMBL21277396 | 0.72 | ALB (0.41) | ALBDNMT1CACNA1FLMNAMAPT | |
| SCHEMBL21277416 | 0.72 | ALB (0.41) | ALBDNMT1CACNA1FLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1878720-A1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |